Is azithromycin adequate treatment for asymptomatic rectal chlamydia?

Area of Science:

• Infectious Diseases
• Sexual Health
• Public Health

Background:

• Rectal chlamydia is a common sexually transmitted infection (STI) among men who have sex with men (MSM).
• This infection is often asymptomatic, complicating diagnosis and treatment.
• The efficacy of the standard single-dose azithromycin treatment for rectal chlamydia lacks robust evidence from randomized trials.

Purpose of the Study:

• To evaluate the real-world efficacy of a single oral dose of azithromycin for treating asymptomatic rectal chlamydia in MSM.
• To determine the rate of treatment failure and re-infection in this population.

Main Methods:

• A retrospective case-note review was conducted at the Sydney Sexual Health Centre.
• Data from 116 MSM diagnosed with asymptomatic rectal chlamydia and treated with azithromycin in 2009 were analyzed.
• Follow-up re-testing rates and outcomes were examined, with behavioral data reviewed to differentiate treatment failure from re-infection.

Main Results:

• Of 116 MSM treated, 85 (73%) attended for follow-up re-testing.
• Persistent positive results were observed in 11 men (13% of those re-tested).
• Analysis suggested a 94% treatment efficacy, with 5 cases classified as possible treatment failures and 6 as probable re-infections.

Conclusions:

• The study suggests a high efficacy (approximately 94%) for single-dose azithromycin in treating rectal chlamydia among MSM.
• Given the lack of RCT data, encouraging re-testing at 6-12 weeks post-treatment is crucial for managing rectal chlamydia.
• Further randomized controlled trials are needed to definitively establish treatment efficacy.